Alzheimer's Disease

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health outcomes, such as dementia and stroke, a new analysis published in Nature Medicine showed.

Consumption of certain teas and coffee may have positive effects on neural network maintenance that could bode well for the prevention of symptoms indicative of Alzheimer’s disease, according to research published in Nutrients.

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat individuals with mild cognitive impairment or mild dementia consistent with early stage Alzheimer’s disease.

Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests should only be ordered if the results will directly impact care, like when determining treatment eligibility.

Placental growth factor, a blood-based protein, may be a reliable method to detect abnormalities in the brain that presage cognitive impairment indicative of Alzheimer’s disease, data show.

Younger age at type 2 diabetes diagnosis was significantly associated with elevated dementia risk, especially for individuals with obesity, according to results published in PLOS One.

Music may help improve cognitive function among people undergoing chemotherapy, according to results of a preliminary study.

A new guideline published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association summarizes best practices for specialists and primary care providers on how to evaluate patients with suspected Alzheimer’s disease or related disorders.

Healio Neurology looks back at the most popular Q&As with industry and specialty experts from the past year.

Healio Neurology looks back at the most-viewed stories during the past year. Highlights include Biogen’s discontinuation of Aduhelm and a former NIH neuroscience director found guilty of research misconduct.